Austedo (deutetrabenazine) works by reducing the amount of dopamine available in your brain. It belongs to a class of drugs called VMAT2 inhibitors, and it’s approved to treat two conditions: the involuntary jerking movements (chorea) associated with Huntington’s disease, and tardive dyskinesia, a movement disorder that can develop as a side effect of certain psychiatric medications. Symptom improvement can begin as early as two weeks after starting treatment.
How Austedo Reduces Involuntary Movements
The core problem behind both Huntington’s chorea and tardive dyskinesia involves excess dopamine signaling in parts of the brain that control movement. Austedo targets this by blocking a protein called VMAT2, which sits inside nerve cells and acts like a loading dock. Normally, VMAT2 packages dopamine into tiny storage compartments (vesicles) so it can be released when the nerve fires. When Austedo blocks VMAT2, dopamine can’t get loaded into those compartments. The unpackaged dopamine sitting loose in the cell gets broken down by enzymes before it ever reaches the gap between nerve cells.
The result is less dopamine released with each nerve signal. This is a reversible process: the drug doesn’t permanently alter your nerve cells. If you stop taking Austedo, dopamine packaging returns to normal. This reversibility also means the drug needs to be taken consistently to maintain its effect.
What Makes It Different From Tetrabenazine
Austedo is a modified version of an older drug called tetrabenazine, which works through the same VMAT2-blocking mechanism. The key difference is a chemistry tweak called deuteration: specific hydrogen atoms in the molecule have been swapped for deuterium, a heavier form of hydrogen. This sounds minor, but it has a meaningful practical effect.
The heavier deuterium atoms create stronger chemical bonds that are harder for liver enzymes to break apart. This slows down how quickly your body deactivates the drug’s active components. In a head-to-head comparison in healthy volunteers, deuteration nearly doubled the half-life of the active compounds and more than doubled overall drug exposure in the bloodstream, without significantly increasing the peak concentration. In practical terms, the drug lasts longer in your system at a more stable level. This means fewer doses per day and potentially smoother symptom control with fewer peaks and valleys.
How Effective It Is
In a 12-week clinical trial for tardive dyskinesia, patients taking Austedo saw their involuntary movement scores drop by 3.0 points on average, compared to 1.6 points for placebo. That difference was statistically significant. For both tardive dyskinesia and Huntington’s chorea, measurable improvements in movement scores showed up as early as week two of treatment in clinical trials.
The degree of improvement varies from person to person. Because the drug is titrated gradually (more on that below), it can take several weeks to reach the dose that works best for you. The full benefit typically becomes clearer over the course of the 12-week titration and stabilization period used in the clinical trials.
How the Dose Is Adjusted
Austedo isn’t started at full strength. For Huntington’s chorea, the starting dose is 6 mg once daily. For tardive dyskinesia, it’s 12 mg per day, split into two doses. From there, your dose can be increased by 6 mg per week until your symptoms are adequately controlled, up to a maximum of 48 mg per day. Once your total daily dose reaches 12 mg or higher, it’s split into two doses taken at different times of day.
The tablets need to be taken with food and swallowed whole. This slow, weekly titration lets your body adjust gradually and helps your doctor find the lowest effective dose, which matters because side effects are dose-dependent. If the drug is interrupted for more than a week, the titration process generally needs to start over.
How Your Genetics Affect the Drug
Austedo is broken down in the liver by a specific enzyme system. Some people carry gene variants that make this enzyme work more slowly. These individuals, called poor metabolizers, clear the drug from their bodies at a reduced rate, which means the same dose produces higher drug levels in their blood. Your doctor may order a genetic test before or during treatment to check for this. Poor metabolizers and people taking other medications that compete for the same liver enzyme may need a lower maximum dose to avoid side effects like excessive drowsiness or restlessness.
Important Safety Risks
Austedo carries an FDA black box warning, the most serious safety designation, specifically for patients with Huntington’s disease. Because Huntington’s disease already increases the risk of depression and suicidal thoughts, and because Austedo further reduces dopamine (a chemical involved in mood regulation), the combination can worsen depression or trigger suicidal thinking. The drug is contraindicated in patients who are suicidal or who have untreated or inadequately treated depression.
This warning applies specifically to the Huntington’s disease population, where depression and suicidal ideation are already more common as part of the disease itself. Patients, caregivers, and family members are asked to watch for new or worsening mood changes, withdrawal, or unusual behavior and report these promptly. For people taking Austedo for tardive dyskinesia, depression monitoring is still recommended, though the risk profile is different because the underlying disease context is different.
What to Expect Day to Day
Common side effects include drowsiness, fatigue, diarrhea, and dry mouth. These tend to be most noticeable during the titration phase as your dose increases. Because the drug reduces dopamine broadly, not just in movement-related brain circuits, some people experience a general feeling of sluggishness or low energy, particularly at higher doses.
The immediate-release version is taken twice daily with food. An extended-release formulation (Austedo XR) is also available, designed to simplify the dosing schedule. Because the drug’s effects are reversible, involuntary movements will typically return if you stop taking it. This isn’t a sign that the condition has worsened; it reflects the drug’s mechanism. Austedo manages symptoms rather than altering the underlying disease process.